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Mutations in the p53 tumor suppressor gene and accumulation of its protein in breast tissue are thought to play a role in
breast carcinogenesis. However, few studies have prospectively investigated the association of p53 immunopositivity and/or p53
alterations in women with benign breast disease in relation to the subsequent risk of invasive breast cancer. We carried out a
case-control study nested within a large cohort of women biopsied for benign breast disease in order to address this question.
After exclusions, 491 breast cancer cases and 471 controls were available for analysis. Unconditional logistic regression was used
to estimate odds ratios (OR) and 95% conﬁdence intervals (95% CI). Neither p53 immunopositivity nor genetic alterations
in p53 (either missense mutations or polymorphisms) was associated with altered risk of subsequent breast cancer. However,
the combination of both p53 immunopositivity and any p53 nucleotide change was associated with an approximate 5-fold
nonsigniﬁcant increase in risk (adjusted OR 4.79, 95% CI 0.28–82.31) but the conﬁdence intervals were extremely wide. Our
ﬁndings raisethe possibilitythat the combination of p53 protein accumulation and the presence of genetic alterations may identify
a group at increased risk of breast cancer.
1.Introduction
Mounting evidence suggests that cancer results from a se-
ries of mutations in genes involved in cell growth and dif-
ferentiation, DNA repair, and cell cycle control [1, 2]. In the
case of breast cancer, a series of genetic changes that develop
over time is believed, in most cases, to drive the morphologic
progressionfromproliferativediseasewithoutatypiatoatyp-
ical ductal hyperplasia and then to ductal carcinoma in situ
and ultimately invasive ductal carcinoma [3]. The actual se-
quenceofgeneticandmolecularchangesunderlyingthepro-
gression from normal breast tissue to invasive cancer has not
been characterized, but the p53 tumor suppressor gene is
thought to play a role [4].
Mutations in the p53 gene are among the most com-
mon genetic alterations found in breast cancer, occurring in
30–50% of cases of sporadic breast cancer [4, 5]. There is a
correlation between the presence of p53 mutations and high
histologic grade, lack of ER and/or PR expression, and less
favorable prognosis [4, 6–11]. p53 mutations have varying
eﬀects, including prolonged expression of an altered p53
protein or, alternatively, the loss of protein expression [4].
Hence,p53mutationsdonotnecessarilyresultinp53protein
accumulation [5, 12–14], indeed, p53 protein accumulation
has been found in association with missense but not trun-
cation mutations [5, 14]. Although p53 mutations can occur
atdiﬀerentlocations in thep53 gene,most mutations tendto
occurintheDNA-bindingmotifswithinexons5–8[4,6–11].
p53 mutations and/or p53 protein accumulation have been
reported in 13% to 70% of invasive intraductal carcinomas
of the breast [5, 15–23] and have also been detected in ductal2 Journal of Oncology
carcinoma in situ [5, 20–22], in benign breast disease [24–
28], in normal-appearing breast tissue [28], and in women at
high risk of breast cancer [29]. Taken together, these ﬁndings
suggest that p53 changes may play a role in the pathogenesis
of breast cancer.
Most previous studies of p53 in benign breast tissue have
examined the prevalence of p53 immunopositivity and/or
p53 mutations in case series, often involving only a limited
number of cases [24–29]. Few studies have prospectively in-
vestigated the association of p53 immunopositivity and/or
p53 alterations in women with benign breast disease in re-
lation to the subsequent risk of invasive breast cancer. In
two previous studies, we showed that women who were im-
munopositive for p53 in normal or benign breast tissue had
a 2- to 2.5-fold increased risk of developing subsequent inva-
sive breast cancer [30, 31]. p53 nucleotide changes overall
were not associated with risk [31], whereas nonpolymorphic
intronic changes in p53 were associated with increased risk
of progression to invasive breast cancer [31]. Results of our
previous analysis suggested that the combination of im-
munopositivity and mutation status identiﬁed a subgroup at
increased risk of subsequent breast cancer better than either
variable alone [31]. However, these results were based on a
relatively small number (n = 104) of breast cancer cases. In
the present study, conducted in a diﬀerent study population
comprising a large cohort of women biopsied for benign
breast disease, we investigated the association between p53
proteinaccumulationandp53mutationsinexons5to10and
subsequent risk of breast cancer.
2.MaterialsandMethods
2.1. Study Population. We carried out a case-control study
nested within a cohort of 15,809 women who received a
breast biopsy either at Guy’s Hospital (London, UK) or with-
in the Kaiser Permanente Northwest (KPNW) health care
system (Portland, OR USA). At Guy’s Hospital, women were
enrolled from 1946 to 1984 and at KPNW from 1970–1994.
Women were eligible to participate if they had a histopatho-
logic diagnosis of benign breast disease (BBD) on their index
biopsy and were at least 21 years old at the time of the index
biopsy. A detailed description of the study has been pub-
lished previously [32].
2.2. Risk Factor Data. I n f o r m a t i o no ns o c i o d e m o g r a p h i c
factors, reproductive and menstrual history, medical history,
family history of breast cancer, and exogenous hormone use
was obtained from medical records [33].
2.3. Followup and Ascertainment of Breast Cancer. For the
London cohort, the National Health Service Central Register
provided information on breast cancer diagnoses and deaths
of cohort members. In Portland, cases were ascertained
throughz linkage to the KPNW cancer registry. Followup in
London continued until 12/31/2003 and in Portland until
12/31/2001.
2.4. Case and Control Deﬁnition. C a s e sw e r ew o m e nw h o
had a biopsy for BBD with a subsequent diagnosis of in
situ or invasive breast cancer. In both cohorts, controls were
women who had a biopsy for BBD and who were alive but
had not developed breast cancer during the same follow-up
period as that for their corresponding case and they were
individually matched to cases (1:1) on age and on age at
diagnosis of BBD (with additional matching in the Portland
cohort on the duration of membership in Kaiser Permanente
health plan). The controls were selected with replacement
andwereeligibletobeselectedagainascontrolsortobecome
cases subsequently. For this reason, although 1,065 women
were selected from the two cohorts, there were a total of
1,092 records (Table 1). After exclusion of women who had
breast cancer prior to baseline, who had no breast tissue, or
were missing pathology data, 962 records were available for
analysis (491 case records and 471 control records). Com-
pared to women retained in the analysis, women who were
excluded had a lower mean age at enrollment (39.0 versus
49.0 years), were more likely to be premenopausal (68.8
versus 52.1%), to be nulliparous (40.0 versus 19.5%), and to
have had an earlier age at menarche 28.4 versus 19.7%, and
were less likely to have a family history of breast cancer in a
ﬁrst-degree relative (5.9 versus 15%).
2.5. Acquisition of Tissue and Histopathologic Review. For
the present study, formalin-ﬁxed paraﬃn-embedded blocks
of benign breast tissue were retrieved from tissue archives.
Hematoxylin and eosin-stained sections from the tissue
blocks were reviewed histologically and classiﬁed according
to the criteria developed by Page and Anderson [34]
and without knowledge of the case-control status of the
study subjects. Histology was categorized as nonprolifera-
tive/normal pathology, proliferative disease without atypia,
and proliferative disease with atypia [32].
2.6. p53 Immunostaining. Sections (5μm) were cut from
the paraﬃn blocks, mounted on aminopropyltriethoxysilane
coated slides (2%; Sigma Chemical Co., St. Louis, Mo, USA),
and deparaﬃnized. The sections underwent antigen retrieval
(microwaved in 10mmol/L citrate buﬀer (pH 6.0) for 15
minutes at a medium-high setting), and immunostaining
was performed as described previously using antibody re-
active with p53 (DO-7; monoclonal; dilution, 1:100; Nov-
ocastra Laboratories, Newcastle upon Tyne, UK) [30]. Im-
munoreactivitywasdetectedusingABCEliteSystem(Vector,
Calif) and DAB as the chromogen. Positive controls were
sections from a paraﬃn-embedded breast cancer that was
known to have a p53 mutation associated with p53 protein
accumulation. Negative controls consisted of replacing the
primary antibody with Universal Negative Control Mouse
(Dako, Calif). Immunostaining and review of the immunos-
tained slides were done without knowledge of the case-
control status of the study subjects. Cytoplasmic staining was
considered nonspeciﬁc and interpreted as negative. Any
nuclear staining of epithelial cells was considered a positive
reaction. The percentage of immunopositive cells was esti-
mated and categorized into 0, >0–<1%, 1–9%, ≥10% total
epithelial cells. p53 staining was present either in a few cellsJournal of Oncology 3
Table 1: Number of cases and controls by center and exclusions.
London Portland Total
Number of unique individuals 452 613 1065
(i) Number of controls used an additional 1× 07
(ii) Number of controls used an additional 2× 03
(iii) Number of controls that reappear as cases 8 6
Total number of records 460 632 1092
(i) Number of case records 230 316 546
(ii) Number of control records 230 316 546
Exclusions (breast cancer before baseline, no breast tissue, missing pathology data) 128 2 130
(i) Cases records excluded 53 2 55
(ii) Control records excluded 75 0 75
Total number of records after exclusions (used in unmatched analysis) 332 630 962
(i) Cases after exclusions 177 314 491
(ii) Controls after exclusions 155 316 471
T o t a ln u m b e ro fw o m e na f t e re x c l u s i o n s 326 611 937
Total number of case-control sets (used in matched analysis) 1481 3161 464
1Matched pairs only.
or all the cells of either a single or multiple ducts. Often the
staining was seen in a single focus of ducts or in multiple foci
within the tissue. We have reported previously that there was
approximately 93% agreement (κ = 0.64) on the presence
or absence of p53 immunostaining in the benign specimens
reread by the same reviewer without knowledge of the result
of the ﬁrst reading [30].
2.7. p53 Mutation Analysis. Two 10 μm-thick sections were
cut from the paraﬃn blocks, dewaxed, and stained brieﬂy in
hematoxylin.Thebreastepitheliumwasmicrodissectedfrom
the stroma (for ﬁbroadenomas, the entire lesion was taken),
collected in a microfuge tube, and digested with proteinase
K (Life Technologies, Burlington, ON, Canada; 0.5mg/mL
in 50mmol/L Tris-HCl (pH 8.5), 10mmol/L EDTA, 0.5%
Tween 20) for at least 24 hours at 55◦C. Proteinase K was
inactivated by heating to 95◦C for 15 minutes. The DNA was
ampliﬁed by PCR using the primers for exons 5 to 10 and
conditions listed in Table 2.T h ep r o d u c tw a sr u no na2 %
agarose gel, the band excised, and DNA extracted using
Qiagen gel extraction kit (Qiagen, Miss, CAN). The puri-
ﬁed DNA was manually sequenced using the CEQ DICS
Quickstart kit (Beckman Coulter, CAN) according to the
manufacturer’s instructions in both directions using either
sense or antisense primers and the CEQ8000 gene analysis
system. If a change was detected, the DNA underwent repeat
PCR and sequencing in the direction that had given the
clearest proﬁle in the ﬁrst sequencing reaction. All sequences
with a nucleotide change and approximately 20% of random
samples negative for p53 alterations were rereviewed by
another observer (RAK or SL). p53 mutation analyses were
performed without knowledge of case-control status.
2.8. Subjects Available for Analysis. Of the 937 women (962
records) available for analysis, blocks of paraﬃn-embedded
benign breast tissue were obtained and immunohistochem-
ical/molecular analysis was completed for 884 women: 453
(92.3%)ofthe491casesand431(91.5%)ofthe471controls.
Seventy-eight women (38 cases and 40 controls) were miss-
ing immunohistochemical results either because tissue sam-
ples were not obtained or because there was no breast epi-
thelium in the tissue sections, rendering them unsuitable
for immunohistochemical analysis. p53 sequencing results
were available for 780 records (404 cases/376 controls) for
exon 5, 788 records (399 cases/389 controls) for exon 6, 792
records (403 cases/389 controls for exon 7, 786 records (402
cases/382 controls) for exon 8, 797 records (407 cases/390
controls)forexon9,and719records(366cases/353controls)
forexon10.Sequencingresultsforallexonswereavailablefor
651 records (329 cases/322 controls).
2.9. Statistical Analysis. In order to make use of all available
data we carried out an unmatched analysis and estimated
odds ratios (OR) and 95% conﬁdence intervals (95% CI)
for the association between immunohistochemically detect-
ed p53 protein accumulation and p53 changes detected by
sequencing using unconditional logistic regression models
[35]. p53 changes were examined overall (i.e., present/ab-
sent) and according to whether they were mutations or poly-
morphisms. The combined eﬀects of immunopositivity and
nucleotide alterations were also examined. Two sets of OR
estimates were computed: (1) using models including terms
for the matching factors (center, age at enrollment, and years
of followup) and (2) using models including the matching
factors, as well as histology (nonproliferative, proliferative),
history of breast cancer in a ﬁrst-degree relative, age at me-
narche, age at ﬁrst live birth, number of pregnancies, and
menopausal status (premenopausal, perimenopausal, and
postmenopausal). (Women who reported having had a men-
strual period within the last year, or who had had a hyster-
ectomy without bilateral oophorectomy and were <45 years
old,wereclassiﬁedaspremenopausal.Womenwereclassiﬁed
as postmenopausal if they had ceased having menstrual peri-
ods at least 12 months earlier without surgical intervention,4 Journal of Oncology
Table 2: p53 primer sequences and PCR conditions.
Primers Sequences Size PCR conditions
Exon 5 5 -GCTGCCGTGTTCCAGTTGCT-3 
294bp 95◦C, 50sec; 58◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -CCAGCCCTGTCGTCTCTCCA-3 
Exon 6 5 -GGCCTCTGATTCCTCACTGA-3 
199bp 95◦C, 50sec; 55◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -GCCACTGACAACCACCCTTA-3 
Exon 7 5 -TGCCACAGGTCTCCCCAAGG-3 
196bp 95◦C, 50sec; 56◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -AGTGTGCAGGGTGGCAAGTG-3 
Exon 8 5 -CCTTACTGCCTCTTGCTTCT-3 
225bp 95◦C, 50sec; 55◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -ATAACTGCACCCTTGGTCTC-3 
Exon 9 5 -GCCTCAGATTCACTTTTATCACC-3 
152bp 95◦C, 50sec; 56◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -CTTTCCACTTGATAAGAGGTCCC-3 
Exon 10 5 -TGATCCGTCATAAAGTCAAACAA-3 
236bp 95◦C, 50sec; 56◦C, 50sec; 72◦C, 60sec, 35 cycles
5 -GGAGTAGGGCCAGTAAGGG-3 
hadhadabilateraloophorectomy,orhadhadahysterectomy
only and were >55 years old. The remaining women were
classiﬁed as perimenopausal.) Matched analyses were also
carried out using conditional logistic regression. Finally, we
performed a sensitivity analysis excluding breast cancer cases
diagnosed during the ﬁrst 3 years of followup. All statistical
tests were two-sided, and P values <0.05 were considered to
be statistically signiﬁcant. The design of the original study,
laboratory assays, and statistical analysis all conform to the
REMARK guidelines [36].
3. Results
Compared to controls, cases were more likely to have pro-
liferative disease with atypia and to have a family history of
breast cancer in a ﬁrst-degree relative (Table 3). Cases were
also more likely to have had a later age at ﬁrst birth and to be
nulliparous. Other factors diﬀered little between cases and
controls.
p53 immunopositivity was not associated with altered
risk of subsequent breast cancer (Table 4). Furthermore, risk
variedlittlebythepercentofcellsshowingimmunopositivity
(Table 4).
Presence of p53 staining (percent cells staining positive:
0, >0–<1, 1–9, ≥10) was strongly associated with presence
of hyperplasia (present versus absent, P<0.0001). The pro-
portionsofwomenwithhyperplasia(present/absent)byper-
cent cell staining positive were 57.8%/86.1%, 21.1%/6.5%,
14.9%/5.9%, and 6.2%/1.5%. Overall histological category
(nonproliferative, proliferative without atypia, atypical hy-
perplasia) was also associated with the presence of p53
staining, P = 0.03. Presence versus absence of any genetic
alteration was not associated with histological category—
P = 0.88 (data not shown).
For cases and controls, the proportions showing any p53
alteration on mutation analysis were 4.8% and 5.5%, respec-
tively (Table 5). Of the alterations in cases, 17 were missense
mutations and 7 were polymorphisms; the corresponding
numbers for controls were 16 and 7. Risk of breast cancer in
association with these alterations did not diﬀer from the
null. No deletions, insertions, nonsense mutations, silent
mutations, or splice site mutations were detected.
When p53 protein accumulation and nucleotide changes
were examined jointly, compared to women who had neither
p53 immunopositivity nor any p53 nucleotide change,
women who were positive for one variable but not the other
were not at increased risk of subsequent breast cancer
(Table 6). Only 3 cases and 2 controls had evidence of both
immunopositivity and a nucleotide change. The combina-
tion of both p53 immunopositivity and any p53 nucleotide
change was associated with an approximate 5-fold, non-
signiﬁcant increase in risk (fully adjusted OR 4.79, 95% CI
0.28–82.31) with extremely wide conﬁdence intervals.
Results of the matched pair analyses were generally con-
sistent (both in direction and magnitude of the risk esti-
mates) with those of the unmatched analyses.
When cases diagnosed within the ﬁrst 3 years of followup
were excluded from the analysis, the results were unchanged
(data not shown).
4. Discussion
In this large case-control study nested within a cohort of
women biopsied for benign breast disease, p53 immunopos-
itivity was not independently associated with increased risk
of breast cancer. Mutation analysis revealed a low frequency
of p53 changes, and these were not associated with increased
risk. However, there was a suggestion that the combination
of immunopositivity and the presence of a p53 mutation was
associated with substantially increased risk, but the number
of women in this group was small and the conﬁdence inter-
vals were very wide.
In an earlier case-control study nested within a cohort
of 4,888 women diagnosed with benign breast disease [30],
p53 protein accumulation was associated with an increased
risk of progression to breast cancer (OR 2.55, 95% CI 1.01–
6.40).Similarchangeswerenotobservedinthecurrentstudy
likely because of the diﬀerences in the exons evaluated and
the primers utilized. In the original study exon 4 was also
evaluated and the primers utilized also included the ﬂank-
ing intronic regions. In a subsequent analysis of the sameJournal of Oncology 5
Table 3: Baseline characteristics of the study subjects.
Variable Cases (N = 491) Controls (N = 471) P value∗
N (%) N (%)
Age at biopsy
<40 109 (22.2) 105 (22.3)
40 to <50 169 (34.4) 166 (35.2)
50 to <60 107 (21.8) 102 (21.7)
60 to <70 69 (14.1) 62 (13.2)
≥70 37 (7.5) 36 (7.6) 0.99
Histology
Nonproliferative disease 137 (27.9) 173 (36.7)
Proliferative disease
without atypia 322 (65.6) 289 (61.4)
Proliferative disease
with atypia 32 (6.5) 9 (1.9) < 0.0001
Age at menarche
<12 76 (20.0) 74 (19.5)
12 87 (22.9) 77 (20.3)
13 109 (28.7) 116 (30.5)
≥14 108 (28.4) 113 (29.7) 0.80
Missing 111 91
Age at ﬁrst live birth
Nulliparous 95 (21.9) 73 (17.3)
≥30 58 (13.4) 34 (8.1)
25–<30 88 (20.3) 96 (22.8)
20–<25 150 (34.6) 177 (41.9)
<20 43 (9.9) 42 (10.0) 0.02
Missing 57 49
Parity
Nulliparous 95 (19.3) 73 (15.4)
Parous 392 (79.8) 391 (83.0) 0.13
Missing 4 7
Number of pregnancies
None 95 (19.8) 73 (16.3)
1 80 (16.4) 69 (14.8)
2 152 (31.1) 157 (33.6)
3 83 (17.0) 91 (19.5)
≥4 77 (15.7) 74 (15.8) 0.83
Missing 4 7
Menopausal status
Premenopausal 264 (53.8) 237 (57.0)
Perimenopausal 39 (7.9) 34 (7.2)
Postmenopausal 188 (38.3) 200 (38.3) 0.27
Ever used hormone therapy
No 350 (71.3) 317 (67.3)
Yes 141 (28.7) 154 (32.7) 0.18
Family history of breast cancer in a ﬁrst-degree relative
No 386 (82.7) 394 (83.8)
Yes 81 (17.3) 57 (12.0) 0.05
Missing 24 20
∗Based on likelihood-ratio-chi-square test.6 Journal of Oncology
Table 4: p53 immunopositivity in benign breast tissue and risk of breast cancer.
Variable Level No. of cases No. of controls ORa (95% CI) ORb (95% CI)
Immunopositive Absent 370 345 1.0 (reference) 1.0 (reference)
Present 83 86 0.95 (0.62–1.44) 0.88 (0.57–1.37)
Missing 38 40
% cells immunopositive
0 370 345 1.00 (reference) 1.00 (reference)
>0–<1 42 39 1.25 (0.69–2.26) 1.27 (0.68–2.35)
1–9 30 37 0.75 (0.40–1.39) 0.68 (0.36–1.32)
≥10 11 10 0.74 (0.26–2.10) 0.57 (0.20–1.64)
Missing 38 40
aAdjusted for center, age at enrollment, and years of followup.
bAdjusted for age at enrollment, center (city), years of followup, histology (nonproliferative, proliferative disease), family history (no, yes), age at
menarche (<12,12,13,14–19), age at ﬁrst birth (continuous), number of pregnancies (continuous), and menopausal status (premenopausal, perimenopausal,
postmenopausal).
Table 5: Association of p53 exonic changes in DNA extracted from benign breast tissue and breast cancer.
Type of exonic change Level No. of cases No. of controls ORa (95% CI) ORb (95% CI)
Any change Wild type 301 294 1.0 1.0
Present 24 25 1.46 (0.60–3.56) 1.03 (0.40–2.65)
Missing 166 152
Deletions Wild type 301 294 NA NA
Present 0 0
Missing 190 177
Insertions Wild type 301 294 NA NA
Present 0 0
Missing 190 177
Nonsense mutations Wild type 301 294 NA NA
Present 0 1
Missing 190 176
Missense mutations Wild type 301 294 1.0 1.0
Present 17 15 2.42 (0.89–7.29) 1.47 (0.48–4.52)
Missing 173 162
Silent mutations Wild type 301 294 NA NA
Present 0 1
Missing 190 176
Splice site mutations Wild type 301 294 NA NA
Present 0 0
Missing 190 177
Polymorphism Wild type 301 294 1.0 1.0
Present 7 7 0.59 (0.12–2.86) 0.47 (0.08–2.96)
Missing 183 170
NA: not applicable.
aAdjusted for center, age at enrollment, and years of followup.
bAdjusted for age at enrollment, center (city), years of followup, histology (nonproliferative, proliferative disease), family history (no, yes), age at
menarche (<12,12,13,14–19), age at ﬁrst birth (continuous), number of pregnancies (continuous), and menopausal status (premenopausal, perimenopausal,
postmenopausal).Journal of Oncology 7
Table 6: Association of p53 protein accumulation and p53 nucleotide changes in benign breast tissue and risk of breast cancer.
p53 change Level No. of cases∗ No. of controls∗ ORa (95% CI) ORb (95% CI)
Immunopositivity and/or
nucleotide change
Both absent 235 227 1.0 (reference) 1.0 (reference)
Immuno +, change − 65 63 1.17 (0.73–1.91) 1.10 (0.66–1.84)
Immuno −, change + 21 23 1.35 (0.53–3.44) 0.89 (0.33–2.40)
Immuno +, change + 3 2 5.60 (0.27–115.3) 4.79 (0.28–82.31)
Missing 167 156
∗38 cases/40 controls missing information on immunopositivity; 0 cases/0 controls missing information on nucleotide changes; 38 cases/40 controls missing
information on combined variable.
aAdjusted for center, age at enrollment, and years of followup.
bAdjusted for age at enrollment, center (city), years of followup, histology (nonproliferative, proliferative disease), family history (no, yes), age at
menarche (<12,12,13,14–19), age at ﬁrst birth (continuous), number of pregnancies (continuous), and menopausal status (premenopausal, perimenopausal,
postmenopausal).
cohort [31], p53 immunopositivity in benign breast tissue
wasassociatedwitha2-foldincreaseintheriskofsubsequent
breast cancer, whereas the presence of any type of p53
nucleotide change in the benign tissue was not associated
with altered risk. When immunoreactivity and nucleotide
changeswereexaminedjointly,however,thosewithbothp53
immunopositivity and a p53 nucleotide change (all chan-
ges combined) had a 3-fold increase in breast cancer risk
[31]. We are aware of three other prospective studies of p53
changes or protein accumulation in normal or benign breast
tissue in relation to risk of subsequent breast cancer [25, 27,
29], but these had had small numbers of breast cancer cases.
The most common p53 mutations occurring in sporadic
breast cancer cases are missense point mutations or inframe
deletion/insertion mutations, which account for 53–73% of
all p53 mutations in these subjects [4]. Because the p53 pro-
teins expressed by these mutant genes have a prolonged half
life, they are detectable using immunohistochemical tech-
niques.However,27–47%ofp53mutationsinvolvenonsense
point mutations or frameshift deletion/insertion mutations
that result in truncated proteins, which are not detected by
immunohistochemistry [4]. In view of the limited concor-
dance between the presence of mutations and the presence
of protein overexpression and the many points at which p53
functioncanbedisrupted,thejointeﬀectofbothfactorsmay
betteridentifyagroupatincreasedriskofinvasivebreastcan-
cer. Findings from our earlier analysis [31]a sw e l la so u r
current results appear to support this. However, the small
number of women exhibiting both immunopositivity and
any genetic alteration in both studies precluded the exami-
nation of speciﬁc types of mutations.
Mostbenignbreastdiseaseisassociatedwithonlyamod-
erately increased risk of progressing to cancer, whereas the
small subgroup with atypical hyperplasia is at substantially
increased risk of progression [27, 32]. We previously re-
ported that, relative to women with BBD/normal pathology,
women with proliferative lesions but without atypia had a
multivariable-adjusted odds ratio for breast cancer of 1.45
(95% CI 1.10–1.90) and women with atypical hyperplasia
had an odds ratio of 5.27 (95% CI 2.29–12.15) [32]. In spite
of the large size of the cohort from which cases and controls
were selected for the present study, the number of women
with atypical hyperplasia was too small to permit separate
analysis of this subgroup. For this reason, extended followup
of large cohorts or pooling of a number of cohorts of women
with benign breast disease is needed to make it possible to
examine p53 protein accumulation and mutations, and their
combined eﬀects, in the subset of BBD with the highest risk
of progression (i.e., those with atypical hyperplasia).
It has been proposed that mutations in the p53 gene ob-
served in benign breast tissue may lead to genetic instability
anddefectiveDNArepairand,ultimatelytoclonalexpansion
oftransformedcellsandprogressiontoinvasivebreastcancer
[24]. Point mutations can contribute to the inactivation of
t u m o rs u p p r e s s o rg e n ef u n c t i o no rt ot h ea c t i v a t i o no fp r o -
tooncogenes [4], whereas DNA ampliﬁcation can activate
protooncogenes[4].However,Soussi[37,38]hasrecentlyar-
gued that the role of p53 genetic alterations in carcinogen-
esis is much more complicated than has been generally re-
cognized. He emphasized that there is a broad spectrum of
heterogeneous p53 mutations and that the eﬀects of these
mutations can be modiﬁed by gene-gene interactions, pro-
tein-protein interactions, and tissue-speciﬁc factors. This
suggests that a more comprehensive assessment and under-
standingoftheroleofp53alterationsintheetiologyofbreast
cancer would require simultaneous assessment of the com-
plex network of overlapping pathways and regulating factors.
Strengths of the current study include the large cohort of
women who underwent a breast biopsy at two collaborating
centers and were followed for an average of 14 years, the
availability of immunohistochemical and p53 mutation re-
sults for >90% of cases and controls, and the ability to adjust
formajorbreastcancerriskfactors.Adjustmentfortheserisk
factorsappearedtoattenuatetheORformissensemutations.
An additional strength is the fact that p53 analyses were
performedwithoutknowledgeofcase-controlstatus,making
diﬀerential bias in the assessment of p53 status unlikely.
Sequencing was used to identify gene alterations, but this
method is inﬂuenced by the amount and quality of DNA.
Furthermore, the number of samples suitable for analysis
was limited by the age of the samples and by variation in
the types of ﬁxatives. Ninety-nine percent of samples from
Portlandwereformalinﬁxed,and99%ofthosefromLondon
were ﬁxed with Formal saline. We repeated the analysis of8 Journal of Oncology
immunopositivity (present/absent) and of any genetic alter-
ation(present/absent)bycenter,andtheresultsdidnotdiﬀer
from the overall results, although the statistical power was
limited.
Several additional limitations of the study should be
mentioned.Paraﬃn-embeddedblocksofbenignbreasttissue
were not obtained for 8% of cases and controls. When
women lacking immunohistochemistry results (N = 78)
were compared to those with results (N = 884) with re-
spect to baseline characteristics, apart from a diﬀerence in
mean age (55.7 for the former and 48.4 for the latter), few
diﬀerences were seen. When women lacking sequencing
results (N = 318) were compared to those with sequencing
results (N = 644), again, aside from a diﬀerence in mean
age (52.1 for the former versus 47.4 for the latter), other
background characteristics were similar. Finally, the small
number of women who showed both immunopositivity and
genetic alterations precluded ﬁrm conclusions about the
eﬀect of these factors in combination and, also, precluded
examination of speciﬁc mutations.
In conclusion, the ﬁndings from this study suggest that
the combined assessment of p53 overexpression and muta-
tions in women with normal or benign breast tissue may
identify a subgroup at increased risk of developing inva-
sive breast cancer. However, the functional signiﬁcance of
diﬀerent genetic alterations and their possible role in the
progression culminating in invasive breast cancer needs to
be elucidated. It also remains to be determined whether p53
immunohistochemical and mutation analysis can improve
ontheuseofhistologyintheclinicalassessmentofawoman’s
risk of breast cancer.
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